Zepbound International Purchase Legalities: What You Need to Know in 2026

Why Importing Zepbound Personally Is Almost Always Illegal

U.S. Federal law prohibits the importation of prescription drugs that are not FDA-approved, that lack proper labeling, or that enter outside authorized distribution channels. This applies regardless of whether the drug is identical in formulation to its U.S.-approved counterpart.

The Governing Statute

The Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331) makes it a federal violation to introduce into interstate commerce any drug that is adulterated, misbranded, or not approved for use in the United States under its specific labeling and lot-number controls. The FDA's own guidance page on personal importation states directly: "In general, it is illegal for individuals to import drugs into the United States for personal use." [1]

Zepbound purchased in Canada, Mexico, the United Kingdom, Germany, or any other country will carry foreign-market labeling and will not have been distributed through the FDA-regulated U.S. Supply chain. Both of those facts independently trigger the prohibition.

The "Personal Importation Enforcement Discretion" Myth

Some websites claim that the FDA allows individuals to import a 90-day supply of a drug for personal use. That claim is misleading. The FDA's 1988 personal importation guidance describes a narrow set of conditions under which the agency may exercise enforcement discretion, meaning it may choose not to act. Those conditions include: the drug is for a serious condition; no effective domestic alternative exists; the quantity does not exceed a personal-use amount; and the individual provides written confirmation it is for personal use. [1]

Zepbound fails the "no effective domestic alternative" test. FDA-approved tirzepatide for weight management is available domestically. The agency has stated explicitly that enforcement discretion does not apply when an FDA-approved drug with the same active ingredient and indication is commercially available in the United States. [1]

What Happens at the Border

U.S. Customs and Border Protection (CBP) works alongside the FDA to screen incoming packages and baggage. Prescription drugs found without valid U.S. Prescriptions, proper U.S.-market labeling, or in quantities exceeding personal-use thresholds may be seized without compensation. [2] The package is typically destroyed or returned at the importer's cost. Repeat violations can result in civil or even criminal referral to the Department of Justice under 21 U.S.C. § 333.

Travelers returning from abroad with Zepbound purchased at a foreign pharmacy face the same seizure risk. A cooler bag of auto-injector pens at an international arrival terminal is not invisible to CBP agricultural and pharmaceutical inspection teams.

How International Prices Compare to U.S. Prices

The price gap between the United States and other high-income countries is real and substantial. Understanding it helps explain why patients search for international options, even if those options carry legal risk.

Tirzepatide Pricing by Country (2025 Data)

In the United Kingdom, tirzepatide (marketed as Mounjaro by Lilly) launched in 2023 at approximately £175 per month for the 2.5 mg starting dose through the NHS drug tariff. In Canada, provincial formulary listings ranged from CAD $280 to CAD $420 per month as of late 2024, depending on the province and dose. Germany's GKV statutory insurance system negotiated a price that works out to roughly €190 per monthly supply at mid-maintenance dosing. [3]

Against a U.S. WAC of approximately $1,059.87 per four-pen carton (roughly $265 per pen), the out-of-pocket gap is stark for Americans without insurance coverage.

Why the Gap Exists

Most other developed nations use centralized price negotiation or reference pricing frameworks. The United States historically relied on market-based pricing, though the Inflation Reduction Act (IRA) of 2022 introduced Medicare drug price negotiation for the first time. Tirzepatide has not yet reached Medicare negotiation status as of early 2026, though it remains a candidate for future cycles. [4]

The price gap does not mean the foreign product is safer or equivalent in terms of U.S. Regulatory standing. It simply reflects different national pricing architectures.

The Compounded Tirzepatide Question

For roughly 18 months between 2022 and 2024, tirzepatide appeared on the FDA's drug shortage list, which permitted compounding pharmacies to produce copies under 503A and 503B exemptions. That window has closed.

FDA Shortage Removal and Its Consequences

The FDA removed tirzepatide from its official drug shortage list in October 2024. [5] Once a drug is removed from the shortage list, the legal basis for compounding under the shortage exemption disappears. The FDA issued warning letters to multiple 503A and 503B facilities continuing to compound tirzepatide after the removal. State pharmacy boards in California, Texas, and Florida subsequently issued their own compliance guidance echoing the federal position.

Patients who received compounded tirzepatide from a telehealth platform after October 2024 may have received a product that was, at the time of dispensing, outside the scope of lawful compounding. This is not a minor distinction. Compounded drugs are not FDA-approved, do not carry the same manufacturing quality standards as Zepbound, and have been associated with overdose errors due to concentration differences. The FDA issued a safety communication on this point in late 2024. [5]

Salt-Form Compounding Workarounds

Some compounding pharmacies pivoted to using tirzepatide salts (acetate or hydrochloride salt forms rather than the base peptide) to argue their products were "different" from FDA-approved tirzepatide and therefore still permissible. The FDA explicitly rejected this argument in a 2024 guidance update, stating that these salt forms are not approved and do not qualify for the shortage exemption. [5] Any telehealth or online pharmacy still advertising "legal compounded tirzepatide" based on salt-form chemistry should be treated with significant skepticism.

Legitimate Ways to Reduce the Cost of Zepbound in the United States

Several options exist that do not require international purchase or compounding.

Lilly's Savings Card Program

Eli Lilly offers a Zepbound Savings Card for commercially insured patients. Eligible patients may pay as little as $25 per month for a 1-month or 3-month supply, subject to a cap of $600 in savings per 28-day supply. [6] Patients without insurance may access a different tier of savings under Lilly's uninsured pricing program. Eligibility is limited to patients with a valid U.S. Prescription who are not enrolled in Medicare, Medicaid, or other federal or state programs.

Patient Assistance Programs

Lilly's Insulin Value Program has served as a model for the company's broader patient assistance architecture. The Lilly Cares Foundation Patient Assistance Program provides free medication to qualifying uninsured or underinsured patients below certain income thresholds. Applications require physician attestation and proof of income. Processing typically takes 2 to 4 weeks. [6]

HSA and FSA Coverage

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) may be used to pay for Zepbound when it is prescribed for an IRS-qualified medical purpose. The IRS defines qualified medical expenses in Publication 502 to include amounts paid for prescription medications. [7]

The key nuance is that Zepbound prescribed solely for cosmetic weight loss (i.e., without a diagnosis of obesity, BMI of 30 or above, or a weight-related comorbidity) may not qualify as an HSA/FSA-eligible expense under strict IRS interpretation. When Zepbound is prescribed for obesity (ICD-10 E66.x) or as part of a treatment plan for type 2 diabetes, hypertension, or obstructive sleep apnea, the case for HSA/FSA eligibility is much stronger. Patients should retain the prescription documentation and the diagnosis code from their clinician for any HSA/FSA reimbursement submission.

Insurance Coverage and Prior Authorization

Most major commercial insurers have tiered Zepbound under specialty formularies with prior authorization requirements. Typical criteria include: BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity; documented failure of behavioral intervention; and absence of contraindications. [8]

The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced a mean weight reduction of 20.9% over 72 weeks compared to 3.1% with placebo (P<0.001). [9] This level of efficacy data is increasingly compelling to payer medical directors reviewing prior authorization criteria, and coverage rates for Zepbound have improved since its 2024 launch.

340B Program Access

Federally Qualified Health Centers (FQHCs), Ryan White clinics, and other 340B-covered entities can purchase Zepbound at federally mandated ceiling prices that are significantly below WAC. Patients receiving care at a 340B entity may access Zepbound at substantially reduced cost if their clinical profile qualifies and the entity has established a Lilly contract. This option is underutilized and worth asking about at community health centers.

State-Level Importation Programs: A Separate Legal Channel

Several U.S. States have passed legislation to create wholesale importation programs from Canada under Section 804 of the FD&C Act, as amended. These are government-to-government or wholesaler-to-wholesaler channels, not individual personal importation.

The framework below clarifies the distinction that causes the most patient confusion.

Wholesale state importation (legal pathway, limited scope): Florida received FDA authorization in January 2024 to import certain drugs from Canada through its state-run program. As of early 2026, tirzepatide is not on Florida's approved importation drug list, because Lilly does not distribute Zepbound in Canada under the same lot-number and serialization system required for FDA import authorization. Colorado, New Hampshire, and Vermont have similar programs with similarly narrow drug lists. [10]

Personal importation by individuals (not covered by these programs): The state wholesale importation programs do not create any right for individual patients to personally import drugs. A patient in Florida cannot point to the state importation law as justification for bringing Zepbound back from a Canadian pharmacy. The authorization is exclusively for licensed wholesalers operating under state health department oversight.

Regulatory Signals to Watch in 2026

Three developments could shift this field within the next 12 to 24 months.

Medicare Negotiation

The IRA authorized the Department of Health and Human Services to negotiate prices for high-expenditure Medicare drugs. The first 10 negotiated drugs (announced August 2023) did not include tirzepatide. The second and third rounds of negotiation are in progress. If tirzepatide enters negotiation, Medicare Part D enrollees could see lower out-of-pocket costs without any importation. [4]

FDA Section 804 Expansion

The FDA has authority to approve additional drugs for the state importation framework. Advocacy groups have petitioned HHS to broaden the list of eligible drugs to include GLP-1 and GIP/GLP-1 agonists. No formal rule has been finalized as of January 2026, but the comment period for a proposed rule closed in late 2025. [10]

Lilly's Direct Pricing Channel

Lilly launched LillyDirect in 2024, a direct-to-patient telehealth and pharmacy channel offering Zepbound at a self-pay price of $399 per month for the 2.5 mg and 5 mg doses. This is substantially below WAC and does not require insurance. It represents a manufacturer-authorized domestic alternative that removes much of the cost-pressure driving patients toward international or compounded sources. [6]

Risks Specific to Online International Pharmacies

Websites advertising Zepbound or tirzepatide for international shipment to U.S. Addresses carry risks beyond legal exposure.

Counterfeit and Substandard Product Risk

The World Health Organization estimates that 10% of medicines in low- and middle-income countries are substandard or falsified. [11] Cold-chain logistics for a peptide drug like tirzepatide, which requires refrigeration between 2 and 8 degrees Celsius, are not reliably maintained across international mail networks. A pen that arrived warm may have degraded active ingredient with no visible change to appearance.

No Recourse for Adverse Events

If a patient experiences a serious adverse event from a product obtained via unauthorized importation, the path to FDA MedWatch reporting is complicated, and the manufacturer bears no liability for product obtained outside its authorized distribution chain. [1]

Verification Tools Do Not Apply

The National Association of Boards of Pharmacy (NABP) runs a Verified Internet Pharmacy Practice Sites (VIPPS) program. VIPPS accreditation applies only to pharmacies licensed to operate within the United States. Foreign pharmacy websites displaying VIPPS-like seals are either misusing the mark or are outright counterfeit. Patients can verify legitimate VIPPS accreditation at nabp.pharmacy directly.

A Practical Decision Checklist Before Considering Any Non-Standard Source

Before a patient considers any non-standard procurement channel, a physician review should confirm the following:

1. Is the patient enrolled in or eligible for the Lilly Savings Card (commercially insured, not federal program)?
2. Has a prior authorization been submitted to the patient's insurer with appropriate ICD-10 coding (E66.01 for morbid obesity, E11.x for type 2 diabetes)?
3. Has the patient's eligibility for 340B pricing through a community health center been assessed?
4. Has the LillyDirect self-pay channel ($399/month) been compared against the patient's current out-of-pocket cost?
5. Has the patient's HSA/FSA balance been reviewed for potential application to the copay?

If all five avenues have been exhausted and cost remains prohibitive, a clinician should document that exhaustion before any off-label or off-channel discussion occurs.